Spruce Biosciences’ (SPRB) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Spruce Biosciences (NASDAQ:SPRB) in a report released on Tuesday,Benzinga reports. HC Wainwright currently has a $200.00 price target on the stock. HC Wainwright also issued estimates for Spruce Biosciences’ Q1 2026 earnings at ($8.92) EPS, Q2 2026 earnings at ($8.20) EPS, Q3 2026 earnings at ($8.08) EPS, Q4 2026 earnings at ($7.56) EPS, FY2026 earnings at ($32.66) EPS and FY2027 earnings at ($14.12) EPS.

Other equities analysts also recently issued reports about the stock. Citizens Jmp set a $259.00 price objective on shares of Spruce Biosciences in a report on Tuesday, November 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Spruce Biosciences in a research report on Monday, December 29th. Leerink Partners raised Spruce Biosciences from a “market perform” rating to an “outperform” rating and set a $160.00 price objective on the stock in a report on Wednesday, December 3rd. Oppenheimer began coverage on Spruce Biosciences in a research note on Tuesday, December 23rd. They issued an “outperform” rating and a $283.00 price objective on the stock. Finally, Wall Street Zen cut Spruce Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, December 27th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Spruce Biosciences has a consensus rating of “Hold” and a consensus target price of $170.10.

Spruce Biosciences Trading Down 6.7%

Shares of NASDAQ SPRB opened at $59.90 on Tuesday. The firm has a market capitalization of $82.06 million, a price-to-earnings ratio of -1.16 and a beta of 3.62. Spruce Biosciences has a one year low of $4.28 and a one year high of $240.00. The business has a fifty day simple moving average of $70.75 and a 200 day simple moving average of $75.74.

Spruce Biosciences (NASDAQ:SPRB) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($9.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($9.16) by ($0.42). On average, research analysts anticipate that Spruce Biosciences will post -1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Spruce Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the company. SkyView Investment Advisors LLC bought a new stake in shares of Spruce Biosciences during the fourth quarter worth $261,000. State Street Corp bought a new position in Spruce Biosciences in the fourth quarter valued at about $558,000. Superstring Capital Management LP bought a new position in Spruce Biosciences in the fourth quarter valued at about $1,057,000. Geode Capital Management LLC acquired a new stake in Spruce Biosciences in the fourth quarter worth about $1,109,000. Finally, Caligan Partners LP bought a new stake in Spruce Biosciences during the 4th quarter worth about $1,787,000. 91.71% of the stock is owned by institutional investors and hedge funds.

Spruce Biosciences Company Profile

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.